AbbVie (ABBV) Q1 Earnings Beat Estimates, Revenues Up Y/Y
Zacks Investment Research | Apr 27, 2017 04:52AM ET
AbbVie Inc. (NYSE:ABBV) reported better-than-expected results in the first-quarter of 2017. The company surpassed both earnings and sales expectations.
In the past one year, AbbVie’s shares gained 3.9%, while the Zacks classified Large-Cap Pharma industry witnessed an increase of 5.9%.
The biopharmaceutical company reported first-quarter 2017 earnings of $1.28 per share that beat the Zacks Consensus Estimate of $1.26 per share by 1.6%. Earnings grew 11% year over year.
The company posted revenues of $6.54 billion in the reported quarter, which surpassed the Zacks Consensus Estimate of $6.51 billion. Revenues also jumped 9.7% year over year. On operational basis revenue increased 10.1%.
Quarter in Detail
Humira sales on an operational basis, excluding currency impact, rose 15.8% year over year to $4.1 billion.
First-quarter net revenue from Imbruvica was $551 million, up 44.7% year over year. U.S. sales of Imbruvica were $457 million. AbbVie recorded $94 million of international profit sharing with Johnson & Johnson (NYSE:JNJ) .
Other products that delivered an impressive performance include Duodopa which showed revenue of $80 million up 22.8% on both operational and reported basis. Another product Creon reported revenue of $185 million up 19.8% and 17% on an operational and reported basis respectively.
HCV product Viekira recorded sales of $263 million, down 15.4% sequentially.
Adjusted SG&A expenses rose 0.7%, while R&D expenses increased 23.3% in the quarter. Adjusted operating margin was 42.3% of sales in the reported quarter.
2017 Outlook
AbbVie reiterated its previously issued outlook for 2017. The company maintains its adjusted EPS in the range of $5.44–$5.54 reflecting growth of 13.9% at the mid-point.
Zacks Rank & Key Picks
AbbVie currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the health care sector are Heska Corporation (NASDAQ:HSKA) and Galena Biopharma, Inc. (NASDAQ:GALE) which sports a Zacks Rank #1 (Strong Buy). You can see .
Heska’s earnings per share estimates increased from $1.53 to $1.65 for 2017 and from $1.80 to $2.01 for 2018, over the last 60 days. The company posted positive surprises in three of the four trailing quarters with an average beat of 291.54%.
Get The News You Want
Galena’s loss per share estimates narrowed from $2.03 to 58 cents for 2017, over the last 60 days. The company posted positive earnings surprises in two of the four trailing quarters with an average beat of 53.83%.
The Best & Worst of Zacks
Today you are invited to download the full, up-to-the-minute list of 220 Zacks Rank #1 "Strong Buys" free of charge. From 1988 through 2015 this list has averaged a stellar gain of +25% per year. Plus, you may download 220 Zacks Rank #5 "Strong Sells." Even though this list holds many stocks that seem to be solid, it has historically performed 6X worse than the market. Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.